ArticleCellular oncology (Dordrecht, Netherlands)2026
NUAK1 silencing enhances radiotherapy-induced ferroptosis in locally advanced rectal cancer by impairing Nrf2-driven transcription of GPX4.
Article in Cellular oncology (Dordrecht, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeRadiotherapy resistance is a primary cause of treatment failure in locally advanced rectal cancer (LARC). Tumor cells can evade radiotherapy-induced ferroptosis by upregulating the antioxidant protein GPX4. NUAK1 is highly expressed in colorectal cancer and associated with poor prognosis, but its role in regulating radiosensitivity remains to be elucidated.
methodsRadiosensitivity was assessed in vitro and in vivo using CCK-8 assays, clonogenic survival assays, and a nude mouse xenograft model. Lipid peroxidation levels were quantified via flow cytometry with C11-BODIPY probe and malondialdehyde (MDA) assay. Ferroptosis-specific mitochondrial morphology was examined by transmission electron microscopy. Nuclear translocation of Nrf2 was detected by nucleocytoplasmic separation experiments and Western blot, while GPX4 promoter and antioxidant response element (ARE) transcriptional activities were measured using dual-luciferase reporter assays. The contribution of ferroptosis was assessed using cell death inhibitors. The Nrf2-specific inhibitor ML385 was utilized to investigate the functional dependency between NUAK1 and Nrf2. Immunohistochemistry (IHC) was used to analyze the correlation between NUAK1 protein expression and radiotherapy response in LARC patients.
resultsNUAK1 knockdown significantly enhanced radiotherapy-induced ferroptosis and radiosensitivity, as evidenced by increased lipid peroxidation, altered mitochondrial morphology, and reduced clonogenic survival. Mechanically, NUAK1 deficiency impaired Nrf2 nuclear translocation and transcriptional activity after radiation, leading to downregulation of GPX4 expression. The Nrf2 inhibitor ML385 completely abrogated NUAK1 overexpression-induced GPX4 upregulation and radioprotection. Clinical sample analysis revealed that high NUAK1 expression was correlated with radioresistance and poor tumor regression.
conclusionThis study is the first to elucidate the critical role of the NUAK1-Nrf2-GPX4 signaling axis in LARC radioresistance. These findings not only reveal a novel mechanism by which tumor cells evade radiotherapy-induced ferroptosis but also provide a potential biomarker and combination therapeutic target for overcoming clinical radioresistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.